Safety and initial efficacy of radiation segmentectomy for the treatment of hepatic metastases

Craig Meiers¹, Amy Taylor², Brian Geller¹, Beau Toskich³

¹Department of Radiology, University of Florida, College of Medicine, Gainesville, FL, USA; ²Department of Radiology, Medical College of Wisconsin, Milwaukee, WI, USA; ³Department of Radiology, Mayo Clinic, Jacksonville, FL, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study material or patients: B Geller, B Toskich; (IV) Collection and assembly of data: C Meiers, A Taylor; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Craig Meiers. Department of Radiology, University of Florida College of Medicine, PO Box 100374, Gainesville, FL 32610-0374, USA. Email: meieca@radiology.ufl.edu.

Background: Hepatic metastatectomy and ablation are associated with prolonged survival, but not all lesions are anatomically amenable to these therapies. We evaluated safety and initial efficacy of segmental ablative transarterial radioembolization, or radiation segmentectomy (RS), as a treatment for hepatic metastases.

Methods: A single institution retrospective analysis was performed of patients with hepatic metastases, determined unamenable to resection by a multidisciplinary tumor board, treated with RS from 2015–2017. Safety parameters evaluated were pre and post procedure liver chemistry, MELD score, ALBI grade, platelet count, and adverse events using both Common Terminology Criteria for Adverse Events (CTCAE) v 4.0 and Clavien Dindo (CD) classifications. Initial efficacy was evaluated using RECIST, mRECIST, and PERCIST criteria.

Results: Ten patients underwent between 1–3 RS treatments. There was no clinical treatment toxicity or significant post-treatment change in liver chemistry, MELD, or ALBI score. One patient had a CTCAE Grade 1/CD Grade 1 adverse event. All patients showed partial or complete imaging response at initial assessment (1–3 months). Seven patients demonstrated disease control at a mean of 7.1 months post treatment. Three patients developed out of field disease progression. One RS was technically unsuccessful.

Conclusions: Early evaluation of segmental radioembolization suggests a safe treatment option for select patients with hepatic metastases. Initial efficacy as definitive radiotherapy with minimal toxicity is promising in anatomic locations unamenable to resection or alternative means of ablation.

Keywords: Hepatic metastases; radioembolization; transarterial radioembolization (TARE); y-90

Submitted Sep 07, 2017. Accepted for publication Oct 20, 2017.
doi: 10.21037/jgo.2017.11.02
View this article at: http://dx.doi.org/10.21037/jgo.2017.11.02

Introduction

Hepatic metastatic disease is common in many malignancies (1) and contributes to severe morbidity and mortality (2,3). Hepatic metastatectomy and thermal ablation are associated with prolonged survival and are sanctioned by multiple guidelines (4–6). Many lesions are not anatomically amenable to resection or thermal ablation (7,8) due to proximity to critical structures, tumor size, indeterminate disease biology, and insufficient residual functional liver.

Transarterial radioembolization (TARE) with Yttrium-90 microspheres has developed a versatile role in the treatment of both primary and metastatic liver disease which includes neo-adjuvant, curative, and palliative applications (9–11). Furthermore, TARE has been used to successfully treat hepatic metastases of multiple other origins including traditionally radioresistant disease such as renal cell carcinoma (12–14). Segmental ablative radioembolization,
or radiation segmentectomy (RS), allows for both increased safety and efficacy when compared to lobar or whole liver treatment by allowing for increased dose and sparing of uninvolved parenchyma (15). Early evaluation of RS in hepatocellular carcinoma with multicenter liver explant and post-resection studies demonstrates 100% and 50–99% necrosis in 52% and 48% of patients and similar tumor control to microwave plus transarterial chemoembolization in a large, propensity score matched, retrospective study (16–20). Our goal was to retrospectively evaluate the safety and initial efficacy of RS as a definitive radiotherapy for hepatic metastases in patients who were poor surgical or thermal ablation candidates.

Methods

Institutional review board approval was obtained for this study. A retrospective chart review of patients with hepatic metastatic disease treated with RS from 8/2015–6/2017 was performed. Inclusion criteria for our patients included liver dominant metastatic disease to the liver confined to two or fewer segments within a single angiosome and denial of surgical intervention by a multidisciplinary tumor board. RS was defined as TARE administered to two contiguous segments or less. Safety parameters evaluated were pre and post-procedure liver chemistry, MELD score, ALBI grade, platelet count, and adverse events using CTCAE v. 4.0 (21) and CD (22) classifications. Yttrium-90 containing glass microspheres and MIRD dosimetry were utilized for all patients. Initial efficacy was evaluated using RECIST 1.1, mRECIST, and PERCIST criteria based on initial and available post-procedure imaging.

Patients underwent pre-procedure mapping angiography utilizing cone beam CT (CBCT) with technetium macroaggregated albumin (MAA) SPECT fusion (23). Dosimetry varied based on tumor to normal liver uptake with an intended administered dose of 120 Gy or greater to the targeted angiosome. All patients subsequently underwent single session outpatient treatment with RS. Follow-up imaging was performed with PET/CT, contrast enhanced CT, or contrast enhanced MRI at means of 1 [1–3], 4 [3–7], and 6 [5–8] months post treatment. Serologic evaluation was performed within the first 3 months with a range of 4–11 weeks. Given the variable primary disease origins and imaging characteristics RECIST 1.1, mRECIST, or PERCIST criteria were utilized to evaluate therapy response based on lesion pretreatment enhancement or FDG uptake.

Results

Ten patients with hepatic metastases (7 colorectal, 1 breast, 1 leiomyosarcoma, 1 carcinoid) underwent 1–3 RS treatments (Table 1). One patient underwent a RS which was technically unsuccessful due to attenuated vascular anatomy. A single patient had a CTCAE Grade 1/CD Grade 1 adverse event consisting of self-limited hiccups following a hepatic dome treatment which may have been secondary to phrenic nerve irritation. There was no clinically significant post-treatment change in AST (mean pre-treatment 28 IU/L, post-treatment 31 IU/L), ALT (mean pre-treatment 28 IU/L, post-treatment 29 IU/L), MELD score (mean pre-treatment 7.0, post-treatment 6.8), ALBI score (mean pre-treatment −2.76, post-treatment −2.62), or platelet count (mean pre-treatment 160,000/mm³, post-treatment 194,000/mm³) at a mean of 3 months. Mean angiosomal radiation volume and dose was 353 mL (47–722 mL) and 261 Gy (119–477 Gy), respectively.

Initial efficacy post RS demonstrated PERCIST complete metabolic responses in five patients [colorectal, leiomyosarcoma, and breast (Figure 1), mean dose 269 Gy, 119–477 Gy], PERCIST partial metabolic response in one patient with one lesion (colorectal, dose 127 Gy), and RECIST 1.1 stable disease in four patients with four lesions (colorectal and carcinoid, mean dose 268 Gy and range, 221–303 Gy). One patient showed progression by mRECIST at 13 months requiring a second treatment (Rectal 1st dose 253 Gy, 2nd dose 281 Gy). Mean progression free survival for this heterogeneous cohort was 7.1 [1–16] months.

One patient who had a PERCIST partial response showed stable disease at 14 months. A single patient who had complete response in two separate lesions developed multifocal disease progression. Nine out of ten patients had systemic chemotherapy and none developed dose limiting hepatotoxicity.

Discussion

The role of TARE for the management hepatic metastases is currently being developed (24,25). Our results suggest that early evaluation of RS, despite administered doses in excess of 470 Gy (26), is a potentially safe treatment option for select patients with hepatic metastatic disease. Transarterial brachytherapy is unique in both the ability to safely deliver predictable and highly conformal ablative radiation doses in close proximity to vulnerable anatomy while allowing for repeat treatments without cumulative organ dose. Advances...
Table 1 Dosimetry, primary tumor origin, toxicity, and response

<table>
<thead>
<tr>
<th>Patient</th>
<th># Tx</th>
<th>Dose (Gy)</th>
<th>Primary</th>
<th>Δ ALBI</th>
<th>Δ MELD</th>
<th>Adverse events</th>
<th>Last imaging response</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3</td>
<td>120–477</td>
<td>Breast</td>
<td>−0.17</td>
<td>0</td>
<td>None</td>
<td>Complete M&amp;P 13 months*; out of field progression at 15 months</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>303</td>
<td>Carcinoid</td>
<td>0.02</td>
<td>0</td>
<td>None</td>
<td>Stable R 6 months*</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>477</td>
<td>Colon</td>
<td>0.02</td>
<td>−3</td>
<td>None</td>
<td>Progressive disease (technically unsuccessful RS)</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>394</td>
<td>Leiomyosarcoma</td>
<td>0.43</td>
<td>0</td>
<td>Phrenic irritation</td>
<td>Complete M&amp;P 8 months*</td>
</tr>
<tr>
<td>5</td>
<td>1</td>
<td>221</td>
<td>Colon</td>
<td>0.43</td>
<td>1</td>
<td>None</td>
<td>Stable R 7 months*</td>
</tr>
<tr>
<td>6</td>
<td>2</td>
<td>119–123</td>
<td>Colon</td>
<td>0.45</td>
<td>−1</td>
<td>None</td>
<td>Complete M&amp;P 4 months*; out of field progression at 7 months*</td>
</tr>
<tr>
<td>7</td>
<td>2</td>
<td>127–290</td>
<td>Colorectal</td>
<td>0.18</td>
<td>0</td>
<td>None</td>
<td>Stable M&amp;P 14 months*</td>
</tr>
<tr>
<td>8</td>
<td>2</td>
<td>253–281</td>
<td>Rectal</td>
<td>0.17</td>
<td>0</td>
<td>None</td>
<td>Complete M&amp;P 16; progression P 18 months*</td>
</tr>
<tr>
<td>9</td>
<td>1</td>
<td>241</td>
<td>Colorectal</td>
<td>−0.15</td>
<td>−1</td>
<td>None</td>
<td>Stable R 1 month*</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>129</td>
<td>Colon</td>
<td>0.08</td>
<td>0</td>
<td>None</td>
<td>Complete M 3 months*</td>
</tr>
</tbody>
</table>

*, evaluation by contrast enhanced CT; †, evaluation by contrast enhanced MR; PET/CT was performed in addition if response is noted as PERCIST. R, RECIST 1.1; M, mRECIST; P, PERCIST; PET, positron emission tomography; CT, computed tomography.

Figure 1 Representative imaging. (A) Pre-procedure PET/CT demonstrates a hypermetabolic breast carcinoma metastasis in segment 4b; (B) pre-procedure CT demonstrates lesion abutting the central bile ducts precluding thermal ablation and a multidisciplinary tumor board had denied the patient a resection; (C) pre-procedure 20 min post Eovist MRI confirms lesion displacing the central bile ducts; (D) post-procedure (1 m) PET/CT demonstrates resolution of metabolic activity of the lesion with expected minor FDG uptake in the treated angiosome; (E) post-procedure (7 m) 20 min post Eovist MRI demonstrates decrease in lesion size and segment volume without ductal obstruction. PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging.

in stereotactic body radiation and proton therapy allow for hypofractionated treatments to select hepatic malignancies (27,28), but are subject to dose constraints, risk of injury to adjacent structures such as bowel, variability due to patient motion requiring fiducial placement, and limitations to repeat administration which are not present in RS.

Of interest, complete metabolic responses were obtained in lesions with minimal to no enhancement or Tc-MAA uptake. While pre-treatment enhancement does not always correlate with response, higher radiation doses conceptually generate higher mEv beta particle events which could mitigate radiation watershed. As RS may be performed as a
single outpatient session (29), offering a minimally invasive definitive radiotherapy with little impact on quality of life and the potential to improve disease free progression is an appealing concept.

Future developments in this approach include dose escalation studies and the consideration for concurrent systemic radiosensitization. Another promising area of exploration is the possible potentiation of immunotherapy, radiotherapy has been shown to be a prolific immunomodulator (30,31).

There are multiple limitations to this study given its retrospective nature, small sample size with variable primary cancers, lack of pathologic correlation, variable imaging schedule and modalities and lack of long-term response data. Many of these factors are inherent to the limited population of patients with metastatic disease who are candidates for RS at this time. Ultimately, whether imaging responses translate to improved survival will require investigation.

Conclusions

Early evaluation of segmental transarterial radioembolization indicates a potentially safe treatment option for select patients with hepatic metastatic disease. Initial efficacy as definitive radiotherapy with minimal hepatic toxicity is promising, particularly in anatomic locations unamenable to resection or alternative means of ablation.

Acknowledgements

None.

Footnote

Conflicts of Interest: B Geller and B Toskich are consultants for BTG plc. The other authors have no conflicts of interest to declare.

Ethical Statement: IRB approval was obtained by the University of Florida (No. 201500230). All patients signed informed consent prior to treatment regarding the collection of treatment data.

References


